← FDA DRUG APPROVALS

FDA ANDA · ANDA040436

DEXTROAMPHETAMINE SULFATE

Sponsor: SPECGX LLC

APPLICATION
ANDA040436
TYPE
ANDA
ORIGINAL APPROVAL
2002-01-29
LATEST ACTION
2023-10-13
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

DEXTROAMPHETAMINE SULFATEPrescription
DEXTROAMPHETAMINE SULFATE 5MG · TABLET · ORAL
DEXTROAMPHETAMINE SULFATEPrescription
DEXTROAMPHETAMINE SULFATE 10MG · TABLET · ORAL

Approval history

2023-10-13Labeling · Supplement 23 · standardAP
2022-02-25Labeling · Supplement 22 · standardAP
2017-01-04Labeling · Supplement 16 · standardAP
2016-10-28Labeling · Supplement 14 · standardAP
2015-04-17Labeling · Supplement 10 · standardAP
2015-01-29Labeling · Supplement 8 · standardAP
2010-04-29Labeling · Supplement 6AP
2008-02-06Labeling · Supplement 5AP
2007-08-31Labeling · Supplement 4AP
2002-01-29OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →